A First-in-Human Study to Test the Safety and Effects of the Investigational Drug IPH4502 in People with Advanced Cancers
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Registration Number
- 2024-519162-46-00
- Lead Sponsor
- Innate Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruiting
- Sex
- Not specified
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Centre Leon Berard
🇫🇷Lyon, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Centre Leon Berard🇫🇷Lyon, FranceArmelle VINCENEUXSite contact+33426556833Armelle.Vinceneux@lyon.unicancer.fr